About: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Sector: Healthcare
Industry: Biotechnology
Latest price: $1.42 (-4.70%)
LXRX NASDAQ Lexicon Pharmaceuticals Inc
Lexicon Pharmaceuticals Inc share price
Atividade de preço de LXRX
Último preço
$ 1,420
Variação (24h)
-0,07 USD (4,70%)
Volume
2.68M
Volume (média 4 sem.)
-
Abertura
$ 1,50
Variação do dia
$ 1,37 - $ 1,50
Fechamento anterior
$ 1,49
Último negócio
23 Oct, 8:16 pm GMT+0
Atrasado
23 Oct, 8:16 pm GMT+0
LXRX price performance
Atrasado
23 Oct, 8:16 pm GMT+0
quote.marketSignals